First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma

Is first-line enfortumab vedotin plus pembrolizumab (EV/P) associated with improved clinical outcomes compared with gemcitabine plus cisplatin (G/C) in patients with metastatic urothelial carcinoma in a multicenter retrospective cohort study?In this cohort study of 4433 patients, first-line EV/P was associated with significantly longer overall survival, lower risk of early hospitalization, and longer time to next treatment compared with G/C. EV/P had a distinct adverse event profile, with fewer hematologic and gastrointestinal toxic effects but more immune-related adverse effects.In this cohort study, EV/P appeared to be an effective and tolerable first-line therapy for metastatic urothelial carcinoma in routine clinical practice.

Corresponding Author: Raj Satkunasivam, MD, MS, Department of Urology, Houston Methodist Hospital, 6560 Fannin St, Ste 2100, Houston, TX 77030 (raj.satkunasivam@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.